Generating CAR T cells against human cognate receptor CD117 may be a successful treatment for patients with AML.
Encouraging response rates in children with first relapse AML treated with CPX-351 followed by FLAG provide rationale for de novo AML study.
The incidence of DLBCL among Hispanic individuals and CLL among non-Hispanic black individuals was associated with urban status.
Novel treatment options are needed to improve outcomes for patients with
TP53</i-mutated myeloid neoplasms.
Two extraction and amplification methods for gene expression analyses on residual leukemic cells may improve future studies when working with fewer cells.
Based on results of pharmacodynamics analyses, the phase 2 study protocol was amended to only include a 100 mg, twice-daily dosing of acalabrutinib.
Pediatric patients with AML may benefit from dexrazoxane as a cardioprotectant during first-line anthracycline therapy.
The Connect CLL Registry revealed that real-world treatment outcomes for patients with CLL who were treated in the community setting differed from trial results.
Smoking associated with inferior survival among patients receiving intensive chemotherapy for AML.
A higher dose of anti-CD19 CAR-T resulted in similar toxicities, but higher ORR and longer PFS, compared with a lower dose in patients with relapsed/refractory CLL.
Acalabrutinib, administered as monotherapy or in combination with obinutuzumab, may be an effective first-line therapy to improve outcomes in CLL.
A first-in-human, universal CAR-T therapy was tolerable and showed activity against relapsed/refractory T-ALL in a phase 1 study.
A novel, bispecific CD19/CD22 CAR-T therapy was tolerable and led to responses in a phase 1, dose-escalating study.
Increased bone marrow
MUC4 expression is associated with reduced remission persistence and exacerbated survival in patients with acute myeloid leukemia.
The FDA has approved the supplemental New Drug Application for Imbruvica® (ibrutinib;Janssen) in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Unrelated donor selection should not be based on KIR in any of the evaluated settings, study results suggest.
A newly developed international prognostic score may be a useful clinical management tool to predict the likelihood of required treatment for patients with early-stage CLL.
Lack of initial response to imatinib might indicate need to switch to dasatinib.
Clinicopathologic and genetic characteristics of therapy-related and de novo core-binding factor AML were studied in a multicenter, retrospective analysis.
Survival outcomes are relatively high for children with ALL but genetics, insufficient chemotherapy treatment, and the risk of relapse may factor into the reduced survival outcomes in adult patients.
Among patients with AML, the type of anthracycline received, and whether some patients undergoing stem cell transplantation have an HLA-identical donor, may not affect long-term outcomes.
T cells targeting CD19/20/22 were also effective in single-cell tracking studies, and appeared as effective as CD19-targeting T cells in CD19-positive disease.
While 85% of nonatopic donors matched with nonatopic recipients remained nonatopic, 61% of atopic donors matched with atopic recipients became nonatopic after AHCT.
Compromised immune status could have effects on disease.
In recent years, the NCCN has updated its clinical practice guidelines to include MRD assessment for MM, ALL, and CLL.
The investigators sought to describe HRQOL and treatment satisfaction of ibrutinib-treated patients with CLL in the real-world setting.
Given the difficulty in definitevely diagnosing acute promyelocytic leukemia, researchers sought to develop a rapid point of care diagnostic assay.
Patients with a NPM1, IDH1, IDH2, or DNMT3A mutation had a complete response or complete response with incomplete hematologic recovery rate of more than 80%.
A review of case studies that outline treatment decisions based on patient and disease characteristics.
Rituximab has some single-agent activity in HCL, but there is evidence that it may eliminate MRD when used with cladribine or pentostatin.
Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.
In this study, epigenetic heterogeneity was not associated with the birth rate of leukemic cells.
Induction regimen FLAG+/-Ida appears to be more effective than 7+3 in patients with non-favorable risk AML, but prospective data are needed.
Patients with acute myeloid leukemia with myelodysplasia-related changes diagnosed on the basis of dysplasia reported improved overall and event-free survival.
The development of a second hematologic malignancy after being diagnosed with chronic lymphocytic leukemia (CLL) appears to be uncommon, a retrospective study found.
Because lead-lined rooms are not always available, the SIERRA trial sought to establish whether mobile shields could provide a suitable alternative for reducing exposure rates.
Researchers summarized risk factors for relapse in acute myeloid leukemia, as well as current and prospective treatment strategies for minimizing relapse risk.
Researchers found that mutated EGR2 and TP53 were significantly associated with worse progression-free survival in patients with chronic lymphocytic leukemia.
A study found that grading systems for assessing toxicities from CAR-T therapy produced inconsistent scores, prompting a call for a more unified grading approach.
Researchers assessed the cytogenetic characteristics of coagulopathy in patients with molecularly distinct acute leukemias.
Continued investigation of Richter transformation may be warranted as new CLL treatments emerge.
Researchers reported long-term follow-up results from the phase 3 RERISE study, which assessed the efficacy of radotinib compared with imatinib for CML treatment.
Risk of a leukemia diagnosis was found to be highest between 3 to 6 years following manifestation of symptoms associated with dengue viral infection.
Researchers assessed whether the incremental cost per quality-adjusted life-year of tisagenlecleucel matched estimated willingness-to-pay thresholds.
Machine learning may help identify newly diagnosed patients with CLL who are at risk for infection or treatment within 2 years of a diagnosis.
Relative survival rates were found to improve for all patient age groups over time, although excess mortality persisted to some degree.
Researchers hypothesized that imbalances of toxic and essential metals in patients with acute myeloid leukemia may be associated with poorer survival.
Patients who were treatment-naive had an overall response rate of 95%, while patients with relapsed/refractory disease had an overall response rate of 92%.
Researchers assessed whether adjusted asparaginase dosage helps reduce toxicity while maintaining sufficient asparaginase depletion in children with ALL.
Mutations were found in 70% of patients, with 53% of patients possessing driver mutations and 17 genes showing mutations in more than 2% of patients.
It’s useful to be aware of misconceptions your patients might have about leukemia. We debunk 6 common myths.